AGA
AZN icon

Accuvest Global Advisors’s AstraZeneca AZN Stock Holding History

Accuvest Global Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,473
Closed -$226K – 79
2025
Q3 		$226K Hold
1,473
– – 0.14% 69
2025
Q2 		$206K Buy
+1,473
New +$206K 0.13% 75

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Accuvest Global Advisors's AZN Position: Q4 2025 in Review

Accuvest Global Advisors sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 1,473 shares — an estimated $226K sold.

Accuvest Global Advisors first reported a position in AZN in Q2 2025 and held it in 2 quarters. The position peaked at $226K in Q3 2025. 1,405 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

  • Accuvest Global Advisors reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
  • Accuvest Global Advisors sold 1,473 AstraZeneca shares in Q4 2025, an estimated $226K.
  • Accuvest Global Advisors first reported a position in AstraZeneca in Q2 2025 and held it in 2 quarters.
  • Accuvest Global Advisors's AstraZeneca position peaked at $226K in Q3 2025.
  • 1,405 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Accuvest Global Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.